Relevance of the MPTP primate model in the study of dyskinesia priming mechanisms

Pierre J. Blanchet, Frédéric Calon, Marc Morissette, Abdallah Hadj Tahar, Nancy Bélanger, Pershia Samadi, Richard Grondin, Laurent Grégoire, Leonard Meltzer, Thérèse Di Paolo, Paul J. Bédard

Research output: Contribution to journalConference articlepeer-review

60 Scopus citations


For nearly 20 years, the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) primate model has allowed great strides to be made in our understanding of the maladaptive changes underlying the levodopa-related motor response complications occurring in most parkinsonian patients. Studies indicate that sustained dopamine D2 receptor occupancy can prevent and reverse existing dyskinesias. Recent experiments in levodopa-treated MPTP animals, co-administered either a threshold dose of cabergoline or a glutamate NMDA NR2B-selective antagonist (CI-1041), have afforded protection against dyskinesia, perhaps through presynaptic inhibition of glutamate release and blockade of supersensitive postsynaptic NMDA receptors in the striatum, respectively. Some of the biochemical events that have correlated with dyskinesias, namely upregulated GABAA receptors in the internal pallidum, rise in pre-proenkephalin-A gene expression in the striatum, and upregulated striatal glutamate ionotropic receptors and adenosine A2a receptors, may be counteracted by these preventive strategies.

Original languageEnglish
Pages (from-to)297-304
Number of pages8
JournalParkinsonism and Related Disorders
Issue number5
StatePublished - Jul 2004
EventStriatal Plasticity in Health and Disease - Stockholm, Sweden
Duration: Nov 28 2003Nov 29 2003

Bibliographical note

Funding Information:
This work was supported by grants from the Canadian Institutes for Health Research (CIHR) to P. Bedard and T. Di Paolo. F. Calon was the recipient of a health professional studentship from Novartis in partnership with CIHR and the Quebec Health Research Fund (FRSQ). The Authors are also grateful to Dr Ali H. Rajput, Royal University Hospital, University of Saskatchewan, for providing human brain tissue. Mrs M.-T. Parent kindly provided assistance in the preparation of the manuscript.

Copyright 2008 Elsevier B.V., All rights reserved.


  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
  • Dyskinesia
  • Parkinson's disease

ASJC Scopus subject areas

  • Neurology
  • Geriatrics and Gerontology
  • Clinical Neurology


Dive into the research topics of 'Relevance of the MPTP primate model in the study of dyskinesia priming mechanisms'. Together they form a unique fingerprint.

Cite this